• Presentation of a selective CB2 receptor agonist acting on microglial cells to improve neuronal functions in Alzheimer’s Disease
• Overview of ongoing and planned clinical trial development focusing on inflammatory effects
• Review strategies to ensure maintenance of avoiding CB1 targeting throughout clinical development

NEW DATA